Meeting
2012 ASCO Annual Meeting
A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors.
Authors
Richard D Baird
University of Cambridge, Department of Oncology, Cambridge, United Kingdom
Richard D Baird , Sophie Papa , Nicola Cresti , Helen Hatcher , Linda Hogarth , Mariam Jamal-Hanjani , Eugene P. Frenkel , Kirsteen Donaldson , John Posner , Izumi Kawabata , Duncan Ian Jodrell , Ruth Plummer , James F. Spicer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Signal Transduction
Clinical Trial Registration Number
2009-017817-31
Citation
J Clin Oncol 30, 2012 (suppl; abstr 3100)
DOI
10.1200/jco.2012.30.15_suppl.3100
Abstract #
3100
Poster Bd #
20B
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors.
First Author: H. S. Han
Poster
2014 ASCO Annual Meeting
Glyco-optimized trastuzumab-GEX, a novel anti-HER2 monoclonal antibody with ADCC activity: A phase I clinical study in patients with HER2-positive tumors.
First Author: Hellmut Samonigg
Poster
2013 ASCO Annual Meeting
A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors.
First Author: Kari Braun Wisinski
Poster
2011 ASCO Annual Meeting
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors.
First Author: M. Simonelli